The chemokine network, a newly discovered target in high grade gliomas

Critical Reviews in Oncology/Hematology

Volumn 79, Issue 2, 2011, Pages 154-163

  Domanska, U M ^a   Kruizinga, R C ^a   den Dunnen, W F A ^a   Timmer Bosscha, H ^a   de Vries, E G E ^a   Walenkamp, A M E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Angiogenesis; Chemokine receptors; Glioma stem cells; High grade gliomas; Infiltration; Targeted therapy

Indexed keywords

1 [5 CHLORO 2 [2 [4 (4 FLUOROBENZYL) 2 METHYL 1 PIPERAZINYL] 2 OXOETHOXY]PHENYL]UREA; CARLUMAB; CELSENTIR; CHEMOKINE; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; DENILEUKIN DIFTITOX; FRACTALKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 8; INTERLEUKIN 8 RECEPTOR; MARAVIROC; MDX 1100; MLN1202; MOGAMULIZUMAB; MONOCYTE CHEMOTACTIC PROTEIN 1; PLERIXAFOR; RALTEGRAVIR; SECONDARY LYMPHOID TISSUE CHEMOKINE; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VICRIVIROC;

ATHEROSCLEROSIS; BRAIN TUMOR; CANCER GRADING; CANCER INHIBITION; CANCER PATIENT; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM TUMOR; CUTANEOUS T CELL LYMPHOMA; DRUG RECEPTOR BINDING; DRUG TARGETING; ENDOMETRIOSIS; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDULLOBLASTOMA; MULTIPLE MYELOMA; NERVOUS TISSUE; NEUROBLASTOMA; NEUROPHYSIOLOGY; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; T CELL LEUKEMIA; TUMOR GROWTH; ULCERATIVE COLITIS;

ANIMALS; ANTINEOPLASTIC AGENTS; ASTROCYTES; BRAIN NEOPLASMS; CELL MOVEMENT; CELL PROLIFERATION; CHEMOKINES; DISEASE PROGRESSION; GLIOMA; HUMANS; MICE; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; NEURONS; RECEPTORS, CHEMOKINE; SIGNAL TRANSDUCTION;

EID: 79957774732     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.07.006     Document Type: Review

References (73)

1. Bajetto A., Bonavia R., Barbero S., Schettini G. Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. J Neurochem 2002, 82:1311-1329.
2. Hannan N.J., Salamonsen L.A. Role of chemokines in the endometrium and in embryo implantation. Curr Opin Obstet Gynecol 2007, 19(3):266-272.
3. Muller A., Homey B., Soto H., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
4. Zlotnik A. Chemokines and cancer. Int J Cancer 2006, 119:2026-2029.
5. Kruizinga R.C., Bestebroer J., Berghuis P., et al. Role of chemokines and their receptors in cancer. Curr Pharm Design 2009, 153396-153416.
6. Harrison J. Constitutive roles for SDF-1/CXCR4 and fractalkine/CX3CR1 in the CNS. In: The biology of chemokine. Universes in delicate balance: chemokines and the nervous system 2002, 237-244. Elsevier, Amsterdam. R.M. Ransohoff, K. Suzuki, A.E.I. Proudfoot, W.F. Hickey, J.K. Harrison (Eds.).
7. Kulbe H., Levinson N.R., Balkwill F., Wilson J. The chemokine network in cancer-much more than directing cell movement. Int J Dev Biol 2004, 48:489-496.
8. O'Hayre M., Salanga C.L., Handel T.M., Allen S.J. Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment. Biochem J 2008, 409:635-649.
9. Stupp R., Mason W.P., Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New Engl J Med 2005, 352:987-996.
10. Rollins B.J. The biology of chemokines. Universes in delicate balance: chemokines and the nervous system 2002, 59-64. Elsevier, Amsterdam. R.M. Ransohoff, K. Suzuki, A.E.I. Proudfoot, W.F. Hickey, J.K. Harrison (Eds.).
11. Haastert P.J.M., Devreotes P.N. Chemotaxis signalling the way forward. Nature 2004, 5:626-634.
12. Lazarini F.O., Tham O., Casanova P., Arenzana-Seisedos F., Dubois-Dalcq M. Role of the chemokine stromal cell-derived factor (SDF-1) in the developing and mature central nervous system. Glia 2003, 42:139-148.
13. Tiveron M.C., Rossel M., Moepps B., et al. Molecular interaction between projection neuron precursors and invading interneurons via stromal-derived factor 1 (CXCL12)/CXCR4 signaling in the cortical subventricular zone/intermediate zone. J Neurosci 2006, 26:13273-13278.
14. Calabrese C., Poppleton H., Kocak M., et al. A perivascular niche for brain tumour stem cells. Cancer Cell 2007, 11:69-82.
15. Chintawar S., Cayrol R., Antel J., Pandolfo M., Prat A. Blood-brain barrier promotes precursor cells. Stem Cells 2009, 27:838-846.
16. Wu Y., Peng H., Cui M., Whitney N.P., Huang Y., Zheng J.C. CXCL12 increases human neural progenitor cell proliferation through Akt-1/FOXO3a signaling pathway. J Neurochem 2009, 109:1157-1167.
17. Stumm R.K., Zhou C., Ara T., et al. CXCR4 regulates interneuron migration in the developing neurocortex. J Neurosci 2003, 23:5123-5130.
18. Super H., Del Rio J.A., Martinez A., Perez-Sust P., Soriano E. Disruption of neuronal migration and radial glia in the developing cerebral cortex following ablation of Cajal-Retzius cells. Cereb Cortex 2000, 10:602-613.
19. Borrell V., Marin O. Meninges control tangential migration of hem-derived Cajal-Retzius cells via CXCL12/CXCR4 signaling. Nat Neurosci 2006, 9:1284-1293.
20. Lu M., Grove E.A., Miller R.J. Abnormal development of the hippocampal dentate gyrus in mice lacking the CXCR4 chemokine receptor. Proc Natl Acad Sci 2002, 99:7090-7095.
21. Pujol F., Kitabgi P., Boudin H. The chemokine SDF-1 differentially regulates axonal elongation and branching in hippocampal neurons. J Cell Sci 2005, 118:1071-1080.
22. Tsai H.H., Frost E., To V., et al. The chemokine receptor CXCR2 controls positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration. Cell 2002, 110:373-383.
23. Meulen A.A.E., Biber K., Lukovac S., et al. The role of CXC chemokine ligand (CXCL)12-CXC chemokine receptor (CXCR)4 signaling in the migration of neural stem cells towards a brain tumour. Neuropath Appl Neurol 2009, 35:579-591.
24. Tham T.N., Lazarini F., Franceschini I.A., Lachapelle F., Amara A., Dubois-Dalcq M. Developmental pattern of expression of the alpha chemokine stromal cell-derived factor 1 in the rat central nervous system. Eur J Neurosci 2001, 13:845-856.
25. Weering H.R., Jong A.P., Haas A.H., Biber K.P., Boddeke H.W. CCL21-induced calcium transients and proliferation in primary mouse astrocytes: CXCR3-dependent and independent responses. Brain Behav Immun 2010, 24:768-775.
26. Robinson S., Tani M., Strieter R.M., Ransohoff R.M., Miller R.H. The chemokine growth-regulated oncogene-a promotes spinal cord oligodendrocyte precursor proliferation. J Neurosci 1998, 18:10457-10463.
27. Bakhiet M., Tjernlund A., Mousa A., et al. RANTES promotes growth and survival of human first-trimester forebrain astrocytes. Nat Cell Biol 2001, 3:150-157.
28. Tani M., Fuentes M.E., Peterson J.W. Neutrophil infiltration, glial reaction and neurological disease in transgenic mice expressing the chemokine N51/KC in oligodendrocytes. J Clin Invest 1996, 98:529-539.
29. Yoshida D., Nomura R., Teramoto A. Signalling pathway mediated by CXCR7, an alternative chemokine receptor for stromal-cell derived factor-1[alpha], in AtT20 mouse adrenocorticotrophic hormone-secreting pituitary adenoma cells. J Neuroendocrinol 2009, 21:481-488.
30. Biber K., Neumann H., Inoue K., Boddeke H. Neuronal 'on' and 'off' signals control microglia. Trends Neurosci 2007, 30:596-602.
31. Limatola C., Lauro C., Catalano M., et al. Chemokine CX3CL1 protects rat hippocampal neurons against glutamate-mediated excitotoxicity. J Neuroimmunol 2005, 166:19-28.
32. Redjal N., Chan J.A., Segal R.A., Kung A.L. CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas. Clin Cancer Res 2006, 12:6765-6771.
33. Shim H., Oishi S., Fujii N. Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors. Semin Cancer Biol 2009, 19:123-134.
34. Woerner B.M., Warrington N.M., Kung A.L., Perry A., Rubin J.B. Widespread CXCR4 activation in astrocytomas revealed by phospho-CXCR4-specific antibodies. Cancer Res 2005, 65:11392-11399.
35. Calatozzolo C., Maderna E., Pollo B., et al. Prognostic value of CXCL12 expression in 40 low-grade oligodendrogliomas and oligoastrocytomas. Cancer Biol Ther 2006, 5:827-832.
36. Rempel S.A., Dudas S., Ge S., Gutierrez J.A. Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. Clin Cancer Res 2000, 6:102-111.
37. Oh J.W., Drabik K., Kutsch O., Choi C., Tousson A., Benveniste E.N. CXC chemokine receptor 4 expression and function in human astroglioma cells. J Immunol 2001, 166:2695-2704.
38. Bajetto A., Barbieri F., Pattarozzi A., et al. CXCR4 and SDF1 expression in human meningiomas: a proliferative role in tumoral meningothelial cells in vitro. Neuro-oncology 2006, 9:3-11.
39. Zhou W., Jiang Z., Song X., et al. Promoter hypermethylation-mediated down-regulation of CXCL12 in human astrocytoma. J Neurosci Res 2008, 86:3002-3010.
40. Zagzag D., Esencay M., Mendez O., et al. Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1/CXCR4 expression in glioblastomas. Am J Pathol 2008, 173:545-560.
41. Salmaggi A., Gelati M., Pollo B., et al. CXCL12 expression is predictive of a shorter time to tumor progression in low-grade glioma: a single-institution study in 50 patients. J Neuro-oncol 2005, 74:287-293.
42. Li M., Ransohoff R.M. The roles of chemokine CXCL12 in embryonic and brain tumor angiogenesis. Semin Cancer Biol 2009, 19:111-115.
43. Rong Y., Durden D., Van Meir E., Brat D. " Pseudopalisading" necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia and angiogenesis. J Neuropathol Exp Neurol 2006, 65:529-539.
44. Kioi M., Vogel H., Schultz G., Hoffman R.M., Harsh G.R., Brown M. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Oncol 2010, 120:694-705.
45. Madden S.L., Cook B.P., Nacht M., et al. Vascular gene expression in nonneoplastic and malignant brain. Am J Pathol 2004, 165:601-608.
46. Liu G., Yuan X., Zeng Z., et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 2006, 5:61.
47. Soeda A., Park M., Lee D., et al. Hypoxia promotes expansion of the CD133-glioma stem cells through activation of HIF-1alfa. Oncogene 2009, 28:3949-3959.
48. Bian X., Yang S., Chen J., et al. Preferential expression of chemokine receptor CXCR4 by highly malignant human gliomas and its association with poor patient survival. Neurosurgery 2007, 61:570-579.
49. Stevenson C.B., Ehtesham M., McMillan K.M., et al. CXCR4 expression is elevated in glioblastoma multiforme and correlates with an increase in intensity and extent of peritumoral T2-weighted magnetic resonance imaging signal abnormalities. Neurosurgery 2008, 63:560-570.
50. DiPersio J.F., Geoffrey L.U., Yasothan U., Kirkpatrick P. Plexirafor. Nat Rev Drug Discov 2009, 8:105-106.
51. Rubin J.B., Kung A.L., Klein R.S., et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci 2003, 100:13513-13518.
52. Brat D.J., Bellail A.C., Van Meir E.G. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro-Oncology 2005, 7:122-133.
53. Nishie A., Ono M., Shono T., et al. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin Cancer Res 1999, 5:1107-1113.
54. Lee S., Jilani S., Nikolova G.V., Carpizo D., Iruela-Arispe M.L. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 2005, 169:681-691.
55. Li A., Dubey S., Varney M.L., Dave B.J., Singh R.K. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003, 170:3369-3376.
56. Leung S.Y., Pik Wong M., Chung L.P., Yee Chan A.S., Yuen Leung S.T. Monocyte chemoattractant protein-1 expression and macrophage infiltration in gliomas. Acta Neuropathol 1997, 93:518-527.
57. Liu C., Luo D., Streit W.J., Harrison J.K. CX3CL1 and CX3CR1 in the GL261 murine model of glioma: CX3CR1 deficiency does not impact tumor growth or infiltration of microglia and lymphocytes. J Neuroimmunol 2008, 198:98-105.
58. Zhou Y., Bian X., Le Y., et al. Formylpeptide receptor FPR and the rapid growth of malignant human gliomas. J Natl Cancer I 2005, 97:823-835.
59. Le Y., Hua J., Gong W., et al. Expression of functional formyl peptide receptors by human astrocytoma cell lines. J Neuroimmunol 2000, 111:102-108.
60. Yao X.H., Ping Y.F., Chen J.H., et al. Glioblastoma stem cells produce vascular endothelial growth factor by activation of a G-protein coupled formylpeptide receptor FPR. J Pathol 2008, 215:369-376.
61. Huang J., Chen K., Gong W., Zhou Y., Bian X., Wang J.M. Receptor " hijacking" by malignant glioma cells: a tactic for tumor progression. Cancer Lett 2008, 267:254-261.
62. Huang J., Hu J., Bian X., et al. Transactivation of the epidermal growth factor receptor by formylpeptide receptor exacerbates the malignant behaviour of human glioblastoma cells. Cancer Res 2007, 67:5906-5913.
63. Haas A.H., Weering H.R.J., Jong E.K., Boddeke H.W.G.M., Biber K.P.H. Neuronal chemokines: versatile messengers in central nervous system cell interaction. Mol Neurobiol 2007, 36:137-151.
64. Ubogu E.E., Cossoy M.B., Ransohoff R.M. The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol Sci 2006, 27:48-55.
65. Liang Y., Bollen A.W., Gupta N. CC chemokine receptor-2A is frequently overexpressed in glioblastoma. J Neuro-oncol 2008, 86:153-163.
66. Galasso J.M., Stegman L.D., Blaivas M., Harrison J.K., Ross B.D., Silverstein F.S. Experimental gliosarcoma induces chemokine receptor expression in rat brain. Exp Neurol 2000, 161:85-95.
67. Kouno J., Nagai H., Nagahata T., et al. Up-regulation of CC chemokine, CCL3L1, and receptors, CCR3, CCR5 in human glioblastoma that promotes cell growth. J Neuro-oncol 2004 Dec, 70(3):301-307.
68. Jordan J.T., Sun W., Hussain S.F., DeAngulo G., Prabhu S.S., Heimberger A.B. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother 2008, 57:123-131.
69. Kalev I., Kaasik A., Zarkovski A., Mikelsaar A.V. Chemokine receptor CCR5 expression in in vitro differentiating human fetal neural stem/progenitor and glioblastoma cells. Neurosci Lett 2006, 394:22-27.
70. Hattermann K., Held-Feindt J., Lucius R., et al. The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Res 2010, 70:3299-3308.
71. Held-Feindt J., Hattermann K., Müerköster S.S., et al. CX3CR1 promotes recruitment of human glioma-infiltrating microglia/macrophages (GIMs). Exp Cell Res 2010, 316:1553-1566.
72. Locatelli M., Boiocchi L., Ferrero S., et al. Human glioma tumors express high levels of the chemokine receptor CX3CR1. Eur Cytokine Netw 2010, 21:27-33.
73. Chemokine/chemokine receptor nomenclature. J Leukocyte Biol 2001, 70:465-466. IUIS/WHO Subcommittee on chemokine nomenclature.